Liposarcoma Market is Expected to be a Competitive Market Until 2019

Tuesday 13 March 2012, Amsterdam

The industry analysis specialist, has released its new report, “Liposarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global liposarcoma market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global liposarcoma sector.

Liposarcoma Therapeutics Market is Forecast to Show High Growth Until 2019

They valued the global (the US, the UK, France, Germany, Italy, Spain and Japan) liposarcoma therapeutics market at $50m in 2011, and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 12.2% to reach $125m in 2019. In the European liposarcoma market there is an approved drug, Yondelis (trabectedin), which is used as a second/third line therapy for the treatment of advanced soft tissue sarcoma (including liposarcoma). The US and Japanese liposarcoma market is dominated by generic chemotherapy drugs such as doxorubicin, ifosfamide and other combinations which are used off-label. The high growth in the market is attributed to the expected launch of late stage novel pipeline drugs such as ridaforolimus in pre-registration, TH-302 in Phase III stage of development in the US, the UK, France, Germany, Italy, Spain and Japan and Yondelis in Phase III stage in the US. These targeted drug therapies with low toxicity are expected to launch in the forecast period. The entry of ridaforolimus would reduce the risk of disease progression in liposarcoma patients.


Promising Pipeline Candidates Provide Hope for the Liposarcoma Treatment Paradigm

There are currently 19 novel molecules under different stages of development in the liposarcoma pipeline. Ridaforolimus (orphan drug exclusivity and fast track status granted by the US FDA and EMEA) is in Pre-registration stage, and TH-302 is in Phase III stage of development in the US, the UK, France, Germany, Italy, Spain and Japan. The orphan drug Yondelis is in Phase III stage of development in the US. There are four company-sponsored First-In-Class (FIC) molecules in the Phase II stage of development. The launch of these molecules could provide treatment options for delaying disease progression. If launched, these novel molecules with enhanced efficacy, safety, tolerability and delayed disease progression could offer better options for patients with liposarcoma.


Liposarcoma Market is Expected to be a Competitive Market Until 2019

The liposarcoma market in the Europe is well served by the currently available option. The only approved drug, Yondelis, is largely being used as a second/third line therapy for the treatment of liposarcoma patients. The generic chemotherapy drugs such as doxorubicin (first-line), ifosfamide (second-line) and combinations such as doxorubicin and ifosfamide, gemcitabine and docetaxel are still used off-label in the US and Japanese market. The launch of ridaforolimus would provide the first new liposarcoma treatment in more than 20 years in the US. This drug could compete with Yondelis due to its positive Phase III outcomes. It might further challenge the usage of Yondelis due to Yondelis’ complicated usage pattern (administered intravenously). The promising pipeline drugs are expected to have improved efficacy, safety and delayed disease progression. These targeted therapies would bring significant competition in the liposarcoma therapeutics market.


Current Approved Therapeutic Drug is successful in Delaying Disease Progression

An analysis shows that the current available approved drug, Yondelis, has displayed high efficacy, low toxicity and delayed disease progression. The chart below shows the efficacy and safety profiles of Yondelis used as a second/third line therapy for the treatment of patients with advanced soft tissue sarcoma (including liposarcoma) in Europe. The unmet need is low in the European liposarcoma market. The unavailability of approved drugs with improved efficacy and safety profiles in order to delay the disease progression and improve survival rates, produces a significant unmet need in the US and Japanese liposarcoma market.